NVIDIA CORP
Long book
$18.37B
Q1 2026
Positions
7
Top-10 weight
100%
concentration
Last quarter
+99.7%
SPY +14.8%
Turnover
29%
of book per quarter
Strategy in plain words
auto-generated from filingsNVIDIA CORP is a diversified fundamental manager, specialised in technology (90% of the long book), running a $18.37B US long book across 7 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: INTEL CORP, COREWEAVE INC-CL A, SYNOPSYS INC, COHERENT CORP, NOKIA CORP-SPON ADR.
Over the last 9 quarters its long book ran on average 31.9pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+16.0%
Q2 2024
-6.1%
Q3 2024
+1.2%
Q4 2024
-17.8%
Q1 2025
+276.4%
Q2 2025
-11.3%
Q3 2025
-42.9%
Q4 2025
+12.4%
Q1 2026
+99.7%
Sector allocation
Technology 89%
Other 11%
Healthcare 0%
Long book by quarter
What does NVIDIA CORP own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| INTC INTEL CORP | Technology | 214.8M | $9.48B | 51.6% | Held |
| CRWV COREWEAVE INC-CL A | Technology | 47.2M | $3.66B | 19.9% | +94.5% |
| SNPS SYNOPSYS INC | Technology | 4.8M | $1.91B | 10.4% | Held |
| COHR COHERENT CORP | Other | 7.8M | $1.86B | 10.1% | New |
| NBIS NEBIUS GROUP NV | Technology | 1.2M | $123.5M | 0.7% | Held |
| GENB GENERATE BIOMEDICINES INC | Healthcare | 833.3K | $10.4M | 0.1% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 7 | $18.37B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 5 | $13.10B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 6 | $3.84B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 6 | $4.33B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 6 | $1.15B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 5 | $304.5M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 6 | $432.9M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 5 | $393.2M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 4 | $332.7M | canonical | SEC ↗ |
Similar funds
Mubadala Investment Co PJSCClear Street Group Inc.Penserra Capital Management LLCWhale Rock Capital Management LLCCircle Wealth Management, LLCJericho Capital Asset Management L.P.THOMA BRAVO, L.P.Altimeter Capital Management, LPDSM CAPITAL PARTNERS LLCExor N.V.WT Asset Management LtdICONIQ Capital, LLC